Xeris Biopharma (NASDAQ:XERS) Stock Rating Raised to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Xeris Biopharma (NASDAQ:XERS) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

XERS has been the subject of several other reports. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price target (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. HC Wainwright boosted their price objective on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Barclays upped their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $12.00 target price (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.20.

Xeris Biopharma Trading Up 16.2%

NASDAQ XERS opened at $15.20 on Friday. The firm has a market capitalization of $2.77 billion, a PE ratio of -303.94 and a beta of 0.61. The stock’s 50 day moving average is $9.62 and its 200 day moving average is $7.62. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $15.21. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 429.43% and a negative net margin of 1.76%. Research analysts forecast that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the sale, the insider directly owned 1,614,208 shares of the company’s stock, valued at $16,142,080. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Several institutional investors have recently made changes to their positions in XERS. Vilga Financial Planning LLC bought a new position in Xeris Biopharma during the third quarter valued at approximately $10,134,000. Legal & General Group Plc purchased a new position in Xeris Biopharma during the 2nd quarter valued at approximately $15,941,000. Walleye Capital LLC bought a new stake in Xeris Biopharma in the 2nd quarter worth approximately $4,841,000. Canada Pension Plan Investment Board bought a new stake in Xeris Biopharma in the 2nd quarter worth approximately $1,736,000. Finally, Bank of America Corp DE bought a new stake in Xeris Biopharma in the 2nd quarter worth approximately $11,065,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.